Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Actinium Pharmaceuticals ( (ATNM) ) has issued an update.
Actinium Pharmaceuticals has appointed Dr. June Almenoff, a seasoned biopharma executive with over 25 years of experience in drug development and leadership, to its Board of Directors. Dr. Almenoff’s extensive background in translational medicine and business development, including leading successful product approvals, is expected to bolster Actinium’s strategic vision and innovation in targeted radiotherapies. Her expertise will be invaluable as Actinium aims to enhance its position in the radiopharmaceutical sector, focusing on innovative treatments for oncology patients.
Find detailed analytics on ATNM stock on TipRanks’ Stock Analysis page.